[go: up one dir, main page]

WO2012041263A3 - Procédé de fabrication d'une 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]- l,3-oxazolidin-5-yl}méthyl)-lh-isoindol-l,3(2h)-dione à la pureté optique élevée - Google Patents

Procédé de fabrication d'une 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]- l,3-oxazolidin-5-yl}méthyl)-lh-isoindol-l,3(2h)-dione à la pureté optique élevée Download PDF

Info

Publication number
WO2012041263A3
WO2012041263A3 PCT/CZ2011/000095 CZ2011000095W WO2012041263A3 WO 2012041263 A3 WO2012041263 A3 WO 2012041263A3 CZ 2011000095 W CZ2011000095 W CZ 2011000095W WO 2012041263 A3 WO2012041263 A3 WO 2012041263A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
isoindol
dione
phenyl
oxazolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2011/000095
Other languages
English (en)
Other versions
WO2012041263A2 (fr
Inventor
Miroslav Urbasek
Pavel Hradil
Martin Grepl
Petra Fialova
Vladimir Oremus
Petr Slezar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmak AS
Original Assignee
Farmak AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmak AS filed Critical Farmak AS
Publication of WO2012041263A2 publication Critical patent/WO2012041263A2/fr
Publication of WO2012041263A3 publication Critical patent/WO2012041263A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne une 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]-l,3-oxazolidin- 5-yl} méthyl)- lH-isoindol- l,3(2H)-dione (I) très pure optiquement obtenue par réaction d'une 2-((2R)-2-hydroxy-3-[4-(3- oxo-4-morpholinyl)phényl]amino-propyl)- lH-isoindol- l,3(2H)-dione (III), contenant l'isomère (2S) (IIIb), avec N,N-carbonyldiimidazole dans du tétrahydrofuranne, de préférence sans la présence du catalyseur 4-diméthylaminopyridine, ladite réaction étant menée de façon à ce qu'elle soit terminée au moment où le mélange réactionnel contient encore le composé n'ayant pas réagi de formule III en quantité allant de 3 à 5 fois la quantité initiale de l'isomère (2S) dans la substance de départ de formule III.
PCT/CZ2011/000095 2010-09-30 2011-09-27 Procédé de fabrication d'une 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]- l,3-oxazolidin-5-yl}méthyl)-lh-isoindol-l,3(2h)-dione à la pureté optique élevée Ceased WO2012041263A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZPV2010-714 2010-09-30
CZ20100714A CZ2010714A3 (cs) 2010-09-30 2010-09-30 Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote

Publications (2)

Publication Number Publication Date
WO2012041263A2 WO2012041263A2 (fr) 2012-04-05
WO2012041263A3 true WO2012041263A3 (fr) 2012-06-21

Family

ID=45418269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2011/000095 Ceased WO2012041263A2 (fr) 2010-09-30 2011-09-27 Procédé de fabrication d'une 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]- l,3-oxazolidin-5-yl}méthyl)-lh-isoindol-l,3(2h)-dione à la pureté optique élevée

Country Status (2)

Country Link
CZ (1) CZ2010714A3 (fr)
WO (1) WO2012041263A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014096214A1 (fr) 2012-12-21 2014-06-26 Farma Grs, D.O.O. Procédé de préparation de rivaroxaban
US20170267669A1 (en) * 2014-08-25 2017-09-21 Cipla Limited Process for the Preparation of Rivaroxaban
CN110054623A (zh) * 2019-05-29 2019-07-26 浙江燎原药业股份有限公司 一种利伐沙班中间体的制备方法
CN111675705A (zh) * 2020-08-11 2020-09-18 北京鑫开元医药科技有限公司 一种4-(4-氨基苯基)吗啉-3-酮衍生物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047919A1 (fr) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Oxazolidinones substituees et leur utilisation dans le domaine de la coagulation sanguine
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425183T3 (es) 2007-08-14 2013-10-11 Concert Pharmaceuticals Inc. Derivados de oxazolidinonas sustituidas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047919A1 (fr) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Oxazolidinones substituees et leur utilisation dans le domaine de la coagulation sanguine
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DISCLOSED ANONYMOUSLY: "Crystalline form of 2-({2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H-dione", IP.COM JOURNAL, vol. 10(6A), no. 17 (ipcom000195959D), 24 May 2010 (2010-05-24), XP002674230, ISSN: 1533-0001 *

Also Published As

Publication number Publication date
CZ2010714A3 (cs) 2012-04-11
WO2012041263A2 (fr) 2012-04-05

Similar Documents

Publication Publication Date Title
MD20130094A2 (en) Process for the preparation of a rivaroxaban and intermediates formed in said process
IL223002A (en) Crystalline Formation of 4 - [5 - [3 - Chloro - 5 - (Trifluoromethyl) Phenyl] - 5,4 - Dihydro - 5 - (Trifluoromethyl) - 3 - Isoxazolyl] - n - [- 2 - Oxo-2 - [( 2,2,2-trifluoroethyl) amino] ethyl] -1-naphthalenecarboxamide
WO2012041263A3 (fr) Procédé de fabrication d'une 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]- l,3-oxazolidin-5-yl}méthyl)-lh-isoindol-l,3(2h)-dione à la pureté optique élevée
PH12012501625A1 (en) Process for the preparation of isoxazoline derivatives
AR083873A1 (es) Derivados de acido amino-fenil-pentanoico sustituidos como inhibidores de nep
WO2010084514A3 (fr) Procédé de préparation de (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl)phényl]-2-oxo-5-oxazolidinyl]méthyl]acétamide
MX2015001114A (es) Metodo para producir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il] piridina-2-carbonitrilo e intermediario del mismo.
BR112015015035A2 (pt) processo integrado para produção de ácido acético
CY1124179T1 (el) Βελτιωμενη μεθοδος παρασκευης ριβαροξαμπανης με χρηση νεων ενδιαμεσων ενωσεων
WO2012099734A3 (fr) Procédé de préparation amélioré de complexes de succinimide de molybdène de faible poids moléculaire
EA201391541A1 (ru) 5-(фенил/пиридинил-этинил)-2-пиридин/ 2-пиримидин-карбоксамиды в качестве модуляторов mglur5
EP2722330A4 (fr) Nouveau procédé pour la synthèse d'un intermédiaire du rivaroxaban, la 4-{4-[(5s)-5-(aminométhyl)-2-oxo-1,3-oxazolidin-3-yl]phényl}morpholin-3-one
EA201490998A1 (ru) Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)-уксусной кислоты
WO2013153492A3 (fr) Procédé de préparation de chlorhydrate de vilazodone et de sa forme amorphe
AR077332A1 (es) Procesos para la alquilacion de pirazoles
MX354414B (es) Derivados de etinilo como moduladores del receptor glutamato metabotropico.
RU2012142223A (ru) Пространственно-затрудненные амины
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
CO6700822A2 (es) Proceso para preparar 3-haloalquilporazoles
NZ598278A (en) Process for preparing biphenyl imidazole compounds
CL2013001882A1 (es) Procedimiento de sintesis industrial del compuesto de formula (i) agomelatina, a partir de cianuro de alilo; compuestos intermediarios.
AR051936A1 (es) Proceso para la preparacion de pirazoles
EA201290592A1 (ru) Способ получения ранелата стронция
CY1112328T1 (el) Νεα διαδικασια συνθεσης της moguisteine
MX2010010416A (es) Formulaciones liquidas y secadas por congelamiento.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11801954

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11801954

Country of ref document: EP

Kind code of ref document: A2